A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses

(2010) Satoshi Hohki et al.   EXPERIMENTAL EYE RESEARCH

Tocilizumab for the treatment of rheumatoid arthritis

(2010) Toshio Tanaka et al.   Expert Review of Clinical Immunology

Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci

(2010) Nobuhisa Mizuki et al.   NATURE GENETICS

Genome-wide association study identifies variants in the MHC class I, IL10 and IL23R-IL12RB2 regions associated with Behçet's disease

(2010) Elaine F Remmers et al.   NATURE GENETICS

Behçet's disease – a contemporary review

(2009) Daniela Mendes et al.   JOURNAL OF AUTOIMMUNITY

Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis

(2009) T. Yoshimura et al.   RHEUMATOLOGY

EULAR recommendations for the management of Behcet disease

(2008) G Hatemi et al.   ANNALS OF THE RHEUMATIC DISEASES

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

Treatment strategies for Behçet's disease

(2008) Izzet Fresko et al.   EXPERT OPINION ON PHARMACOTHERAPY